{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T20:53:48Z","timestamp":1770238428329,"version":"3.49.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s13555-025-01559-z","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:53:08Z","timestamp":1760338388000},"page":"247-259","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk of Nonmelanoma Skin Cancer in Patients with Moderate-to-Severe Atopic Dermatitis: A United States Population-Based Study"],"prefix":"10.1007","volume":"16","author":[{"given":"Mark","family":"Lebwohl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Whitney S.","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Berman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher G.","family":"Bunick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd","family":"Schlesinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayman","family":"Grada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"1559_CR1","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1038\/s41598-021-83502-8","volume":"11","author":"M Ci\u0105\u017cy\u0144ska","year":"2021","unstructured":"Ci\u0105\u017cy\u0144ska M, Kami\u0144ska-Winciorek G, Lange D, et al. The incidence and clinical analysis of non-melanoma skin cancer. Sci Rep. 2021;11:4337.","journal-title":"Sci Rep"},{"key":"1559_CR2","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1186\/s12885-022-09940-3","volume":"22","author":"W Hu","year":"2022","unstructured":"Hu W, Fang L, Ni R, Zhang H, Pan G. Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted level in 25\u00a0years. BMC Cancer. 2022;22:836.","journal-title":"BMC Cancer"},{"key":"1559_CR3","first-page":"288","volume":"63","author":"V Slavinsky","year":"2024","unstructured":"Slavinsky V, Helmy J, Vroman J, Valdebran M. Solar ultraviolet radiation exposure in workers with outdoor occupations: a systematic review and call to action. Int J Dermatol. 2024;63:288\u201397.","journal-title":"Int J Dermatol"},{"key":"1559_CR4","first-page":"2130","volume":"32","author":"EF Chakravarty","year":"2005","unstructured":"Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol. 2005;32:2130\u20135.","journal-title":"J Rheumatol"},{"key":"1559_CR5","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/sj.bjc.6605733","volume":"103","author":"E Lanoy","year":"2010","unstructured":"Lanoy E, Engels EA. Skin cancers associated with autoimmune conditions among elderly adults. Br J Cancer. 2010;103:112\u20134.","journal-title":"Br J Cancer"},{"key":"1559_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i262","volume":"352","author":"P Raaschou","year":"2016","unstructured":"Raaschou P, Simard JF, Asker Hagelberg C, Askling J. Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden. BMJ. 2016;352:i262.","journal-title":"BMJ"},{"key":"1559_CR7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1001\/jamaoncol.2021.5680","volume":"8","author":"MM He","year":"2022","unstructured":"He MM, Lo CH, Wang K, et al. Immune-mediated diseases associated with cancer risks. JAMA Oncol. 2022;8:209\u201319.","journal-title":"JAMA Oncol"},{"key":"1559_CR8","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.3892\/ol.2019.10080","volume":"17","author":"M Neagu","year":"2019","unstructured":"Neagu M, Constantin C, Caruntu C, Dumitru C, Surcel M, Zurac S. Inflammation: a key process in skin tumorigenesis. Oncol Lett. 2019;17:4068\u201384.","journal-title":"Oncol Lett"},{"key":"1559_CR9","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s40257-018-0383-4","volume":"19","author":"A Paller","year":"2018","unstructured":"Paller A, Jaworski JC, Simpson EL, et al. Major comorbidities of atopic dermatitis: beyond allergic disorders. Am J Clin Dermatol. 2018;19:821\u201338.","journal-title":"Am J Clin Dermatol"},{"key":"1559_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/bjd\/ljad072","volume":"189","author":"J Wan","year":"2023","unstructured":"Wan J, Shin DB, Syed MN, et al. Malignancy risk in patients with atopic dermatitis: a population-based cohort study. Br J Dermatol. 2023;189:53\u201361.","journal-title":"Br J Dermatol"},{"key":"1559_CR11","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s13555-022-00720-2","volume":"12","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Wang H, He J, et al. Atopic dermatitis and skin cancer risk: a systematic review. Dermatol Ther (Heidelb). 2022;12:1167\u201379.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1559_CR12","doi-asserted-by":"publisher","first-page":"ii35","DOI":"10.1093\/bjd\/ljad498.037","volume":"190","author":"C Bunick","year":"2024","unstructured":"Bunick C, Chovatiya R, Guttman E, et al. 533 - Long-term 5-year safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis including over 7000 patient-years of exposure. Br J Dermatol. 2024;190:ii35\u20136.","journal-title":"Br J Dermatol"},{"key":"1559_CR13","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1001\/jamadermatol.2024.1536","volume":"160","author":"LA Beck","year":"2024","unstructured":"Beck LA, Bissonnette R, Deleuran M, et al. Dupilumab in adults with moderate to severe atopic dermatitis: a 5-year open-label extension study. JAMA Dermatol. 2024;160:805\u201312.","journal-title":"JAMA Dermatol"},{"key":"1559_CR14","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s40257-023-00792-6","volume":"24","author":"L Stein Gold","year":"2023","unstructured":"Stein Gold L, Tha\u00e7i D, Thyssen JP, et al. Safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: an integrated analysis of eight clinical trials. Am J Clin Dermatol. 2023;24:595\u2013607.","journal-title":"Am J Clin Dermatol"},{"key":"1559_CR15","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1001\/jamadermatol.2019.3786","volume":"156","author":"L Wang","year":"2020","unstructured":"Wang L, Bierbrier R, Drucker AM, Chan AW. Noncutaneous and cutaneous cancer risk in patients with atopic dermatitis: a systematic review and meta-analysis. JAMA Dermatol. 2020;156:158\u201371.","journal-title":"JAMA Dermatol"},{"key":"1559_CR16","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1158\/1055-9965.EPI-14-1243","volume":"24","author":"J Cheng","year":"2015","unstructured":"Cheng J, Zens MS, Duell E, Perry AE, Chapman MS, Karagas MR. History of allergy and atopic dermatitis in relation to squamous cell and basal cell carcinoma of the skin. Cancer Epidemiol Biomark Prev. 2015;24:749\u201354.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1559_CR17","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jaad.2003.09.024","volume":"50","author":"ME Ming","year":"2004","unstructured":"Ming ME, Levy R, Hoffstad O, et al. The lack of a relationship between atopic dermatitis and nonmelanoma skin cancers. J Am Acad Dermatol. 2004;50:357\u201362.","journal-title":"J Am Acad Dermatol"},{"key":"1559_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-071172","volume":"13","author":"MM Hedderson","year":"2023","unstructured":"Hedderson MM, Asgari MM, Xu F, et al. Rates of malignancies among patients with moderate to severe atopic dermatitis: a retrospective cohort study. BMJ Open. 2023;13:e071172.","journal-title":"BMJ Open"},{"key":"1559_CR19","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1038\/jid.2010.115","volume":"130","author":"M Mildner","year":"2010","unstructured":"Mildner M, Jin J, Eckhart L, et al. Knockdown of filaggrin impairs diffusion barrier function and increases UV sensitivity in a human skin model. J Invest Dermatol. 2010;130:2286\u201394.","journal-title":"J Invest Dermatol"}],"updated-by":[{"DOI":"10.1007\/s13555-025-01593-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000}}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01559-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01559-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01559-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:40:16Z","timestamp":1770190816000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01559-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1559"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01559-z","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s13555-025-01593-x","URL":"https:\/\/doi.org\/10.1007\/s13555-025-01593-x","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mark Lebwohl has served as a consultant and\/or received research funds from AbbVie, Almirall, AltruBio Apogee, Arcutis, AstraZeneca, Atomwise, Avotres, Bristol Myers Squibb, Boehringer Ingelheim, Cara, Castle, Celltrion, Clexio, Dermavant, Evommune, Facilitation of International Dermatology Education, Forte, Galderma, Genentech, Incyte, Inozyme, Janssen, LEO Pharma, Lilly, Meiji Seika, Mindera, Pfizer, Sanofi-Regeneron, Seanergy, Strata, Takeda, Trevi, UCB, and Verrica. Mark Lebwohl is an editorial board member of\n                      Dermatology and Therapy.\n                      Mark Lebwohl was not involved in the selection of peer reviewers for the manuscript nor in any of the subsequent editorial decisions. Emma Yue, Whitney S. Krueger, and Ayman Grada were or are full-time employees of AbbVie, and may hold AbbVie stock and\/or stock\u00a0options. Brian Berman has served as consultant and\/or investigator for AbbVie, Aiviva, Almirall, Anacor, Biofrontera, Birch BioMed, BPG Bio, Bristol Myers Squibb, Castle Ferndale, FBM, Galderma, GSK, Lemonex, Mediwound, Minolabs, Novan, Novartis, Ortho Dermatologics\/Valeant, Pfizer, PHD Biosciences, Pulse, Sensus, Sirnanomics, Smith & Nephew, Sun Pharma, and Thirona. Christopher G. Bunick has served as an investigator, consultant, and\/or speaker for AbbVie, Allergan, Almirall, Apogee, Arcutis, Daiichi Sankyo, EPI Health\/Novan, LEO Pharma, Lilly, Novartis, Ortho Dermatologics, Palvella, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, Timber, and UCB. Todd Schlesinger has served as an advisor, investigator, and consultant for AbbVie, Allergan (an AbbVie Company), Almirall, Amgen, Alumis, Apogee, Arcutis, ASLAN, Benev, Biofrontera, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Dermsquared, Eli Lilly and Company, ExoCoBio, Flint Clinical, Galderma, Genentech, Highlightll, HTL Biotechnologies, Incyte, Janssen, L\u2019Oreal, Novartis, Pfizer Inc., RBC Consultants, Regeneron, Rion, Sanofi, SiSaf, Sun Pharma, Takeda, UCB, and Verrica, and has received a salary from Avant-Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This was a noninterventional study that used de-identified secondary data from a commercially available claims database and posed no risk to patients. No institutional review board review or approval was necessary. The study was conducted in accordance with all legal and regulatory requirements.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}